Product Description
A MONOCLONAL ANTIBODY THAT BINDS TO TIGIT, BLOCKING TUMOR IMMUNOSUPPRESSION AND INCREASING IMMUNE ACTIVITY (Sourced from: https://arcusbio.com/domvanalimab/)
Mechanisms of Action: TIGIT Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: Arcus Biosciences
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Bangladesh, Belgium, Brazil, Canada, Chile, China, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Israel, Italy, Japan, Korea, Lithuania, Malaysia, Mexico, Netherlands, Norway, Peru, Philippines, Poland, Portugal, Romania, Serbia, Singapore, Slovakia, South Africa, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Vietnam
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer|Lung Cancer|Lymphoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Squamous Cell Carcinoma
Phase 2: Carcinoma, Adenosquamous|Cholangiocarcinoma|Hepatocellular Carcinoma|Liver Cancer|Melanoma|Pancreatic Cancer
Phase 1: Glioblastoma|Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PACIFIC-8 | P3 |
Active, not recruiting |
Small Cell Lung Cancer|Non-Small-Cell Lung Cancer |
2030-02-23 |
|
| jRCT2061210088 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2029-09-30 |
|
| PACIFIC-8 | P3 |
Recruiting |
Non-Small-Cell Lung Cancer |
2028-06-27 |
45% |
| jRCT2061230073 | P3 |
Not yet recruiting |
Non-Small-Cell Lung Cancer |
2027-12-31 |